Survival Outcomes in Metastatic Castration-Resistant Prostate Cancer (mCRPC) for Black versus White Men-Susan Halabi

(Length of Discussion: 12 min)

Susan Halabi, who is the first biostatistician to become a fellow of ASCO discusses recent data on overall survival in prostate cancer for black versus white men with Alicia Morgans and Charles Ryan.  Susan discusses an analysis that showed an increase in overall survival in African American men vs Caucasian men, all of whom had metastatic castration-resistant prostate cancer (mCRPC) treated with docetaxel/prednisone or a regimen containing those agents.  She outlines the findings and how these may impact clinical practice as well as clinical trial enrollment in men with prostate cancer.

Biographies:

Susan Halabi, Ph.D., Professor of Biostatistics and Bioinformatics, Duke University, member of the Duke Cancer Institute, and a Fellow of the American Society of Clinical Oncology.

Alicia Morgans, MD, MPH
Charles J. Ryan, MD.